JNJ
Healthcare · Pharmaceuticals
256.03
-1.02% · 2026-10-02
Avoid
- Trade priority
- not ranked
- Data coverage
- 55%
- Setup
- no setup · 2026-10-02
- News
- positive
- Next catalyst
- Earnings in 6 sessions
Trade plan
No trade plan: the strategy has no valid setup for this symbol (trend or relative-strength condition fails (intermediate_trend, relative_strength_20)).
Your portfolio · San
- Profile
- Sanequity 2,000.00 USD · whole shares
- Current holding
- noneno open position in this profile
- Recommended quantity
- —no pending entry to size
- Risk budget
- 10.000.5% of 2,000.00
- Portfolio risk
- 0.00 opencap 2%
- Exposure
- 0 / 3 positionsHealthcare: 0 / 2 · 0.00 of 1,000.00 cap
- Cash impact
- 2,000.00derived from the ledger
- Eligibility
- AVOIDsame as the strategy view
Entry, stop, targets and R:R are strategy-owned and identical for every profile; only this portfolio's quantity, risk, exposure and cash differ. Manage profiles · record a fill
Why this action
Technical
- trend or relative-strength condition fails (intermediate_trend, relative_strength_20)
- RS20 vs SPY -7.6%, vs QQQ -12.5%
Options
- volume 2.11× the 20D baseline (neither) · selected contracts only, delayed
News and events
- news context positive (59 canonical items in window)
- high-materiality item with unknown direction
- earnings 2026-10-13 (6 sessions, finnhub); event risk medium
- fda · high · unknown: Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE
- fda · high · unknown: Johnson & Johnson Announces Two-year Data From Its Phase 3 ICONIC-TOTAL Study Of ICOTYDE O
- guidance · high · positive: Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall St
- other · low · unknown: Dave Ramsey Says Single Stocks Are a Gamble. What That Means if You Live on Dividends
Market and risk
- regime RISK ON: SPY: trend UP, volatility NORMAL; QQQ: trend UP, volatility NORMAL
Chart
2026-10-02O 259.38H 259.38L 255.12C 256.03 -1.02%Vol 10,942,147RVOL20 1.73SMA50 266.00SMA150 247.67SMA200 241.71EMA20 266.58RSI14 32.3MACD -1.081 / 0.568 / -1.649ATR14 5.14RS20 SPY -7.6% · QQQ -12.5%
Indicator history is derived from the stored bars with the accepted M3 functions (WORKSTATION_SERIES_V1); the scanner’s persisted values remain authoritative. Reconciliation at the scan session: 8 match.
Trade priority
Not ranked: only valid setups and gated setups enter the trade-priority ranking.
- technical readinessn/a
- structure quality10/10
- relative strength-2/15
- participation10/10
- risk rewardn/a
- news context10/10
- event risk2/5
- urgency1/5
operational attention priority not a return forecast. Missing inputs lower coverage, never the score.
Setup evidence · PRE_BREAKOUT_V1
- Setup state
- NO_SETUP
- Resistance
- 274.2
- Distance
- 6.63%
- Close
- 256.03
- SMA50
- 266
- SMA150 / SMA200
- 247.67 / 241.71
- RSI14
- 32.3
- EMA20 extension
- -2.05 ATR
- RS20 vs SPY
- -7.6%
- RS20 vs QQQ
- -12.5%
Hard requirements · 4/8 passed
- PASSConfirmed resistanceresistance=274.2033 exists eligible=true
- FAILDistance to resistancedistance_pct=6.6277 · resistance=274.2033 · close=256.03 inclusive_between min=0 · max=3
- FAILClose above SMA50close=256.03 · sma50=266.001 > right_operand=sma50
- PASSSMA150 ≥ SMA200sma150=247.6736 · sma200=241.7071 >= right_operand=sma200
- FAILRSI14 bandrsi14=32.2829 inclusive_between min=50 · max=70
- PASSEMA20 extension (ATR)extension_atr=-2.0519 · close=256.03 · ema20=266.5844 · atr14=5.1437 <= max=1.5
- FAILRS20 vs SPY or QQQSPY=-0.0759 · QQQ=-0.1249 OR > SPY=0 · QQQ=0
- PASSResistance qualitydistinct_touches=3 policy_and_minimum_touches min=2
Supporting evidence · 2/6 passed
- PASSATR compressioncurrent_atr_pct=0.0201 · median_previous_60_atr_pct=0.0214 · ratio=0.9386 < right_operand=median_previous_60_atr_pct
- FAILVolume contractionrecent_volume=7,689,373.3018 · baseline_volume=6,343,004.0236 · ratio=1.2123 < max=0.85
- FAILHigher lowslow_1=263.83 · low_2=260.68 · low_3=265.04 low_3 > low_2 > low_1 required_pivots=3
- PASSFull MA alignmentsma50=266.001 · sma150=247.6736 · sma200=241.7071 sma50 > sma150 > sma200
- FAILRS20 vs SPY positiveSPY=-0.0759 > min=0
- FAILRS20 vs QQQ positiveQQQ=-0.1249 > min=0
PRE_BREAKOUT_V1 · scan run 414 · session 2026-10-02 · evaluated as of 2026-10-04T13:22:56.327970Z. Supporting evidence never changes the trigger; UNKNOWN is never collapsed into false.
Intelligence timeline
- 2026-10-0319:06 UTCJohnson & Johnson (NYSE: JNJ) reported new Phase 3 results for oral peptide ICOTYDE in plaque psoriasis at the 2026 EADV Congress. The oral IL-23 inhibitor showed sustained skin clearance and improvement across multiple high-impact psoriasis sites, including in adolescent patients. Johnson & Johnson said ICOTYDE also remains in clinical studies for other major inflammatory diseases beyond plaque p
- 2026-10-0218:45 UTCDave Ramsey has called single stocks a gamble for years, but retirees who pay their bills with dividends from stocks like Johnson and Johnson are making a very different bet. Whether his rule protects them or costs them depends on a risk they may not see coming.
- 2026-10-0213:11 UTCJohnson & Johnson (JNJ) is back in focus after new IMAAVY data in generalized myasthenia gravis, giving investors fresh insight into how its immunology pipeline might complement the stock’s recent double digit one year return. Despite the IMAAVY update and a string of recent drug data releases across immunology, oncology and neuroscience, Johnson & Johnson’s share price has eased in the short term
- 2026-10-0210:00 UTCJohnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact of ICOTYDE® (icotrokinra) on high-impact plaque psoriasis (PsO) sites. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric patients 12 years of age and older (adolescents).
- 2026-10-0206:03 UTCThe late-breaking results, shared as an oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2026, evaluated adults and adolescents with at least moderate high-impact site
- 2026-10-0201:03 UTCBank of America nearly doubled its peak sales estimate for one Johnson & Johnson drug ahead of the company’s third-quarter earnings.
- 2026-10-0119:15 UTCJohnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.
- 2026-10-0116:15 UTCBoth JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.
- 2026-10-0111:45 UTCJACKSONVILLE, Fla., October 01, 2026--New global survey by Johnson & Johnson finds most women don’t connect eye health changes with menopause
- 2026-10-0100:12 UTCJohnson & Johnson (NYSE:JNJ) closed at $264.74 on September 30, almost 43% higher than a year ago and within a few percent of its record. The company is worth about $638 billion and turns 29.19% of its $97.93 billion in revenue into operating profit. READ ALSO: Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid […]
- 2026-09-3019:20 UTCThis is not an exhaustive list.
- 2026-09-3019:13 UTCPepsiCo (NasdaqGS:PEP) has appointed Joaquin Duato, Chairman and CEO of Johnson & Johnson, to its Board of Directors. Duato currently leads Johnson & Johnson, a major global healthcare group with a large portfolio of consumer and pharmaceutical brands. His appointment adds senior healthcare and international experience to PepsiCo's board as the business focuses on health oriented product lines. Th
- 2026-09-3015:30 UTCKey TakeawaysMicrosoft just raised its quarterly dividend 8% to $0. 98, and Johnson & Johnson raised its payout for the 64th straight year in April.
- 2026-09-3014:45 UTCDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
- 2026-09-3006:05 UTCJohnson & Johnson reports Q3 earnings Oct. 13; EPS seen at $2.48, revenue $25.31B. Analysts are mostly bullish after positive Tremfya and Carvykti data.
- 2026-09-3001:10 UTCJohnson & Johnson (NYSE:JNJ) reported new long term IMAAVY data in generalized myasthenia gravis, including adolescent outcomes. The company said adolescents with gMG on IMAAVY showed sustained disease control and reduced reliance on corticosteroids, with no new safety signals. Survey findings from healthcare professionals indicated IMAAVY may address unmet needs for more consistent symptom manage
- 2026-09-2920:45 UTCIn the latest trading session, Johnson & Johnson (JNJ) closed at $267.66, marking a -1.58% move from the previous day.
- 2026-09-2918:42 UTCJohnson & Johnson (NYSE:JNJ)'s oral psoriasis drug Icotyde could reach $4.5 billion in peak sales, up from a previous $2.4 billion estimate, Bank of America said as it raised its price target on the company to $278 from $263. The broker now values estimated 2027 earnings excluding...
- 2026-09-2913:01 UTCAnalysts expect Johnson & Johnson's Q3 FY2027 sales to be in line, but EPS to be below consensus due to IPR&D dilution.
- 2026-09-2912:14 UTCJohnson & Johnson will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.
- 2026-09-2912:03 UTCJohnson & Johnson (NYSE: JNJ) today announced new findings on IMAAVY® (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) across 15 novel abstracts to be presented at the 2026 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. These data include two-year results fro
- 2026-09-2912:00 UTCJohnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 2026-09-2909:30 UTCJP Morgan analyst Chris Schott maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $270 to $285.
- 2026-09-2908:10 UTCJohnson & Johnson has delivered a strong run over the past few years, which naturally raises a question for anyone looking at the stock today. Are investors now paying a price that is fully backed by the cash flows the healthcare group is expected to generate? Over the past 5 years the share price is up 96.4%, which means a lot of future cash generation is already being referenced in the current v
- 2026-09-2908:09 UTCNew two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroid use in
- 2026-09-2822:54 UTCOn September 25, Johnson & Johnson (NYSE:JNJ) announced top-line findings from its Phase 4 STAR study evaluating Tremfya (guselkumab) in biologic-naïve adults with active psoriatic arthritis (PsA) and axial involvement. Tremfya met primary and secondary endpoints, demonstrating improvements in axial symptoms alongside MRI-confirmed reductions in joint inflammation. As the first randomized, placebo
- 2026-09-2819:44 UTCJohnson & Johnson’s (NYSE:JNJ) $14.6 billion acquisition of Intra-Cellular Therapies has gained another potential growth avenue after Caplyta met the main goal of a late-stage study in bipolar mania. J&J said Caplyta significantly reduced symptoms of bipolar mania compared with placebo in the Phase 3 trial. Patients began showing improvement as early as three days […]
- 2026-09-2819:31 UTCGuggenheim has assumed coverage of Nanobiotix S.A. (NASDAQ:NBTX) with a Buy rating and a $64 price target on September 15, putting the company’s Johnson & Johnson-partnered JNJ-1900 at the center of its investment thesis. The analyst’s attention is particularly focused on NANORAY-312, the pivotal Phase 3 study evaluating JNJ-1900 in patients with locally advanced head […]
- 2026-09-2723:12 UTCGilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is expanding faster, powered by an HIV franchise that continues to gain momentum, while Johnson & Johnson isn’t growing as quickly, but its portfolio stretches across pharmaceuticals and MedTech, giving it more ways to absorb weakness […]
- 2026-09-2606:10 UTCJohnson & Johnson (NYSE:JNJ) reported new clinical data for TECVAYLI plus DARZALEX FASPRO, CARVYKTI, and TREMFYA in multiple myeloma and axial psoriatic arthritis. Early line multiple myeloma data suggest TECVAYLI plus DARZALEX FASPRO could align patient mortality risk with that of the general population. CARVYKTI results highlight treatment-free remissions lasting five years in relapsed or refrac
- 2026-09-2513:45 UTCJohnson & Johnson (NYSE:JNJ) said its Tremfya treatment significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 study. The company said Tremfya met the study’s primary endpoint at week 24, showing greater improvement than placebo on a disease...
- 2026-09-1100:50 UTC
- 2026-09-0413:08 UTC
- 2026-09-0120:52 UTC
- hidden28 provider-tagged items never name the company and are kept as context only.
canonical items of the last 10 sessions; analyst/industry/macro commentary and social sources excluded from the direction tally; gating uses tier 1-3 HIGH items within 3 (negative) / 2 (unknown direction) sessions
Catalysts and filings
| Event | Date | In | Materiality | Source |
|---|---|---|---|---|
| Earnings | 2026-10-13 | 6 sessions | high | finnhub · Tier 3 · provider |
Options activity
- Session volume
- 3,014
- 5D baseline
- 1,303
- 20D baseline
- 1,430
- Volume / 20D
- 2.11x
- Call / put volume
- 1,953 / 1,061
- Call / put ratio
- 1.84
- Top-3 contract share
- 65%
- Top expiration
- 2026-10-16 84%
Activity trend · last 30 sessions
| Session | Volume | 5D | 20D | / 20D |
|---|---|---|---|---|
| 2026-09-22 | 1,286 | 2,070 | 1,328 | 0.97x |
| 2026-09-23 | 1,336 | 1,951 | 1,348 | 0.99x |
| 2026-09-24 | 1,257 | 1,983 | 1,396 | 0.90x |
| 2026-09-25 | 808 | 2,030 | 1,439 | 0.56x |
| 2026-09-28 | 3,014 | 1,303 | 1,430 | 2.11x |
Call vs put volume
calls 65%puts 35%
Expiration concentration
Contract concentration
Top contracts · session 2026-09-28
| Contract | Type | Strike | Expiration | DTE | Volume | 5D avg | 20D avg | / 20D | Return | Moneyness |
|---|---|---|---|---|---|---|---|---|---|---|
| O:JNJ261016C00270000 | CALL | 270 | 2026-10-16 | 18 | 1,254 | 116 | 254 | 4.94x | 4.5% | ITM (0.7%) |
| O:JNJ261016P00260000 | PUT | 260 | 2026-10-16 | 18 | 505 | 115 | 317 | 1.59x | -8.9% | OTM (4.6%) |
| O:JNJ261016P00270000 | PUT | 270 | 2026-10-16 | 18 | 195 | 107 | 77 | 2.54x | -1.8% | OTM (0.7%) |
| O:JNJ261016C00275000 | CALL | 275 | 2026-10-16 | 18 | 167 | 155 | insufficient history | insufficient history | -1.0% | OTM (-1.1%) |
| O:JNJ261016C00280000 | CALL | 280 | 2026-10-16 | 18 | 106 | 326 | 356 | 0.30x | 14.2% | OTM (-2.9%) |
| O:JNJ261016P00272500 | PUT | 272.5 | 2026-10-16 | 18 | 106 | insufficient history | insufficient history | insufficient history | 6.3% | ATM (-0.2%) |
| O:JNJ261009C00282500 | CALL | 282.5 | 2026-10-09 | 11 | 83 | 8 | insufficient history | insufficient history | 0.8% | OTM (-3.7%) |
| O:JNJ261009C00272500 | CALL | 272.5 | 2026-10-09 | 11 | 80 | 22 | insufficient history | insufficient history | 10.5% | ATM (-0.2%) |
| O:JNJ261009P00262500 | PUT | 262.5 | 2026-10-09 | 11 | 63 | insufficient history | insufficient history | insufficient history | -9.3% | OTM (3.6%) |
| O:JNJ261009P00265000 | PUT | 265 | 2026-10-09 | 11 | 59 | 36 | insufficient history | insufficient history | -10.3% | OTM (2.6%) |
| O:JNJ261016C00272500 | CALL | 272.5 | 2026-10-16 | 18 | 54 | 16 | insufficient history | insufficient history | 4.4% | ATM (-0.2%) |
| O:JNJ261016C00260000 | CALL | 260 | 2026-10-16 | 18 | 50 | 8 | 104 | 0.48x | 13.7% | ITM (4.6%) |
| O:JNJ261009P00260000 | PUT | 260 | 2026-10-09 | 11 | 45 | 93 | 69 | 0.66x | -9.8% | OTM (4.6%) |
| O:JNJ261009C00275000 | CALL | 275 | 2026-10-09 | 11 | 43 | 32 | insufficient history | insufficient history | -1.5% | OTM (-1.1%) |
| O:JNJ261009C00280000 | CALL | 280 | 2026-10-09 | 11 | 35 | 75 | 72 | 0.48x | 4.8% | OTM (-2.9%) |
OPTIONS_SELECTION_M9_V1 selected contracts only · provider capability DELAYED · delayed · Top 15 selected contracts by session volume; 5D/20D averages use strictly prior sessions (M10), INSUFFICIENT_HISTORY is shown, never zero.
M13 observations for this session
- Technical setup present (PRE_BREAKOUT_V1): FALSE
- Technical and options context share a session: FALSE
- Activity above its own 20-session baseline: TRUE
- Activity below its own 20-session baseline: FALSE
- Recent 5-session baseline above 20-session baseline: FALSE
- Recent 5-session baseline below 20-session baseline: FALSE
- Volume concentrated in top 3 contracts: TRUE
- Volume concentrated in one expiration: TRUE
- Calls carry most session volume: TRUE
- Puts carry most session volume: FALSE
- Call and put volume roughly balanced: FALSE
- Enrichment data (snapshot/OI/IV/Greeks) available: FALSE
- Enrichment data unavailable: TRUE
- Real flow data unavailable: TRUE
- Flow events present in replay window: NOT_EVALUABLE
Flow
Flow events—
Clusters—
Sweep candidates—
Block candidates—
Aggressor candidates—
Premium coverage—
Flow engine is ready. Trades and Quotes are not available with the current provider capabilities; this area populates automatically from the same M11 engine when real persisted facts exist. Synthetic fixture flow is never shown.
Evidence alerts
| Category | Alert | Previous | Current | Sessions | Workflow | Actions |
|---|---|---|---|---|---|---|
| Changed | Options activity vs 20D baseline rose | 0.56 | 2.11 | 2026-09-25 → 2026-09-28 | New | |
| Changed | Top-3 contract concentration increased | 0.41 | 0.65 | 2026-09-25 → 2026-09-28 | New | |
| Changed | Top expiration concentration increased | 0.55 | 0.84 | 2026-09-25 → 2026-09-28 | New | |
| Data quality | Data freshness changed | TECHNICAL=CURRENT_SESSION; OPTIONS_ACTIVITY=STALE; FLOW=MISSING; ACTIVITY_PROVIDER=DELAYED | TECHNICAL=CURRENT_SESSION; OPTIONS_ACTIVITY=DELAYED; FLOW=MISSING; ACTIVITY_PROVIDER=DELAYED | 2026-10-01 → 2026-10-02 | New |
Decision trace
- setup_eligibleFAILNO_SETUP: failed distance_to_resistance, intermediate_trend, relative_strength_20, rsi_bandfailed_conditions=distance_to_resistance, intermediate_trend, relative_strength_20, rsi_band
- finalPASSAVOID
Actions are generated from the configured trading strategy and current available market/intelligence data. They are not guarantees of future performance.